MDM2 gene amplification: A new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 43, Issue 3, 2004, Pages 285-295

  Dworakowska, Dorota ^a   Jassem, Ewa ^a   Jassem, Jacek ^a   Peters, Brigitte ^b   Dziadziuszko, Rafał ^a   Zylicz, Maciej ^c   Jakóbkiewicz Banecka, Joanna ^d   Kobierska Gulida, Grazyna ^a   Szymanowska, Amelia ^a   Skokowski, Jan ^a   Roessner, Albert ^b   Schneider Stock, Regine ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^d INSTITUTE OF OCEANOLOGY   (Poland)

Author keywords

MDM2 gene amplification; NSCLC; Prognostic value

Indexed keywords

OXYGENASE; PHENYLALANINE; PROTEIN MDM2;

ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DNA HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HOUSEKEEPING GENE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MEDICAL ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR DIFFERENTIATION;

EID: 10744230829     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.09.010     Document Type: Article

References (40)

1. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49:1999;33-64.
2. Jassem J., Skokowski J., Dziadziuszko R., Jassem E., Szymanowska A., Rzyman W.et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postsurgical pathological TNM classification. J. Thorac. Cardiovasc. Surg. 119:2000;1141-1146.
3. Zhang R., Wang H. Mdm2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Des. 6:2000;393-416.
4. Fakharzadeh S., Trusko S., Geoge D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1991;1565-1569.
5. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
6. Momand J., Zambetti G.P. Mdm2: big brother of p53. J. Cell Biochem. 64:1997;343-352.
7. Piette J., Neel H., Marechal V. Mdm2: keeping p53 under control. Oncogene. 15:1997;1001-1010.
8. Heines D.S. The mdm2 proto-oncogene. Leuk. Lymph. 26:1996;227-238.
9. Freedman D.A., Wu L., Levine A.J. Function of the MDM2 oncoprotein. Cell Mol. Life Sci. 55:1999;96-107.
10. Daujat S., Neel H., Piette J. MDM2: life without p53. Trends Genet. 17:2001;459-464.
11. Juven-Gershon T., Oren M. Mdm2: the ups and downs. Mol. Med. 5:1999;71-83.
12. Bartel F., Meye A., Wurl P., Kappler M., Bache M., Lautenschlager C.et al. Amplification of the gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer. 95:2001;168-175.
13. Seki A., Kodama J., Miyagi Y., Kamimura S., Yoshinouchi M., Kudo T. Amplification of the mdm2 gene and p53 abnormalities in uterine sarcomas. Int. J. Cancer. 73:1997;33-37.
14. Schneider-Stock R., Walter H., Radig K., Rys J., Bosse A., Kuhnen C.et al. Mdm2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alternations in the oncogenesis of liposarcomas. J. Cancer Res. Clin. Oncol. 124:1998;532-540.
15. Yokoyama R., Schneider-Stock R., Radig K., Wex T., Roessner A. Clinicopathologic implications of mdm2, p53 and K-ras gene alternation in osteosarcomas: mdm2 amplification and p53 mutations found in progressive tumors. Pathol. Res. Pract. 194:1998;615-621.
16. Gunther T., Schneider-Stock R., Hackel C., Kasper H.U., Pross M., Hackelsberger A.et al. Mdm2 gene amplification in gastric cancer correlation with expression of mdm2 protein and p53 alternation. Mod. Pathol. 13:2000;621-626.
17. Qian W., Hu L.F., Chen F., Wang Y., Magnusson K.P., Kashuba E.et al. Infrequent MDM2 gene amplification and absence of gross WAF1 gene alternation in nasopharyngeal carcinoma. Eur. J. Cancer B Oral Oncol. 31B:1995;328-332.
18. Taniere P., Martel-Planche G., Puttawibul P., Casson A., Montesano R., Chanvitan A.et al. TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the oesophagus in south Thailand. Int. J. Cancer. 88:2000;223-227.
19. Quesnel B., Preudhomme C., Fournier J., Fenaux P., Peyrat J.P. Mdm2 gene amplification in human breast cancer. Eur. J. Cancer. 30A:1994;982-984.
20. Ohnishi H., Kawamura M., Hanada R., Kaneko Y., Tsunoda Y., Hongo T.et al. Infrequent mutation of the p53 gene and no amplification of the mdm2 gene in hepatoblastomas. Genes Chromosomes Cancer. 15:1996;187-190.
21. Ruggeri B.A., Huang L., Berger D., Chang H., Klein-Szanto A.J., Goodrow T.et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer. 79:1997;700-716.
22. Dziadziuszko R., Jassem E., Jassem J. Clinical implications of molecular abnormalities in lung cancer. Cancer Treat. Rev. 24:1998;317-330.
23. Gorgoulis V.G., Zoumpourlis V., Rassidakis G.Z., Karameris A., Rassidakis A.N., Spandidos D.A.et al. A molecular and immunohistochemical study of the mdm2 protein isoforms and p53 gene product in bronchogenic carcinoma. J. Pathol. 180:1996;129-137.
24. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S. et al. Mdm2 gene amplfication and expression in non-small cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer. 75:1997;1302-1308.
25. Marchetti A., Buttitta F., Pellegrini S., Merlo G., Chella A., Angeletti C.A.et al. Mdm2 gene amplification and overexpression in NSCLC with accumulation of the p53 protein and absence of p53 gene mutation. Diagn. Mol. Pathol. 4:1995;93-97.
26. Ko J.L., Cheng Y.W., Chang S.L., Su J.M., Chen C.Y., Lee H. Mdm2 mRNA expression is a favorable prognostic factor in non-small cell lung cancer. Int. J. Cancer. 89:2000;265-270.
27. Gorgoulis V.G., Rassidakis G.Z., Karameris A.M., Papastamatiou H., Trigidou R., Veslemes M.et al. Immunohistochemical and molecular evaluation of the mdm2 gene product in bronchogenic carcinoma. Mod. Pathol. 9:1996;544-554.
28. Aikawa H., Sato M., Fujimura S., Takahashi H., Endo C., Sakurada A.et al. MDM2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int. J. Mol. Med. 5:2000;631-633.
29. World Health Organization. Histological typing of lung tumors. 2nd ed. Geneva: WHO; 1981.
30. International Union Against Cancer. TNM classification of malignant tumors. 5th ed. New York: Wiley/Liss; 1997. p. 93-7.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory; 1989.
32. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
33. Schneider-Stock R., Emrich T., Peters B., Jaeger V., Roessner A. Analysis of human telomerase reverse transcriptase mRNA (hTERT) expression in myxoid liposarcomas using LightCycler real-time quantitative reverse transcriptase-polymerase chain reaction. Electrophoresis. 22:2001;1098-1101.
34. Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healey J.H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:1993;16-18.
35. Olson J.J., Barnett D., Yang J., Assietti R., Cotsonis G., James C.D. Gene amplification as a prognostic factor in primary brain tumors. Clin. Cancer Res. 4:1998;215-222.
36. Dworakowska D., Jassem E., Wiedorn K., Dziadziuszko R., Kobierska G., Skokowski J.et al. P53 and mdm2 expression in NSCLC: the lack of prognostic relevance. Eur. Respir. J. 18 Suppl 33(230s):2001;P1591.
37. Fu X.L., Zhu X.Z., Shi D.R., Xiu L.Z., Wang L.J., Zhao S.et al. Study of prognostic predictors for NSCLC. Lung Cancer. 23:1999;143-152.
38. Mitsudomi T., Hamajima N., Ogawa M., Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 6:2000;4055-4063.
39. de Anta J.M., Jassem E., Rosell R., Martinez-Roca M., Jassem J., Martinez-Lopez E.et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene. 15:1997;2951-2958.
40. Dworakowska D., Gozdz S., Jassem E., Badzio A., Kobierska G., Urbaniak A.et al. Prognostic relevance of proliferation cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer. 35:2002;35-41.